Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation outflow grows to $2.08M

Q1 FY2026 stock-based compensation was $2.08M, compared with $0 a year earlier. Trailing-twelve-month stock-based compensation was $6.67M. Over 3 fiscal years it compounded at -9.2% a year.

Context

  • Stock-based compensation amounted to 722.5% of revenue in FY2025, down 837.0 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $2.08M or moves back toward the trailing-twelve-month quarterly average of $1.67M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.08M-6.9% QoQ
Last fiscal yearDec 2025
$11.8M-26.4% YoY
LTMMar 2026
$6.67M-45.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-26.4%——
3-year CAGR-9.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
11.8M USD
Year-over-year change
-26.4%
4-year CAGR
-15.0%

Stock-Based Compensation vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -45.2% is the lowest of 9, against a peer median of +8.6%.
  • Stock-based compensation amounts to 210.3% of revenue for RANI, versus a peer median of 152.7%.
RANI Competitors
Stock-Based Compensation for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$7.48M USD-39.0%-34.0%21.6%
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$7M USD+76.4%-18.0%39.9%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$6.67M USD-45.2%-9.2%210.3%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$6.49M USD-5.6%+3.2%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$6.14M USD+9.4%-6.2%344.3%
CRDFCardiff Oncology, Inc.LTM Mar 2026$5.99M USD+19.7%+10.2%1140.6%
IPHAInnate Pharma S.A.FY2025€4.26M EUR+7.9%+0.1%152.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 4.21M CHF-4.1%-4.6%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$3.05M USD+83.8%+67.0%—
Peer median (excluding RANI) —+8.6%-2.3%152.7%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(8.33M)(63.34M)(33.97M)(56.58M)(29.67M)
Depreciation & Amortization497K548K822K1.03M900K
Deferred Income Tax00000
Stock-Based Compensation22.6M15.78M19.01M16.03M11.8M
Change in Working Capital(3.43M)509K(2.14M)(544K)6.96M
Accounts Receivables000(428K)(1.61M)
Inventory00000
Accounts Payables543K163K(595K)711K(1.05M)
Other Working Capital(3.97M)346K(1.55M)(827K)9.62M
Other Non-Cash Items(43.58M)(10K)(34.96M)4.57M(8.7M)
Operating Cash Flow(32.25M)(46.52M)(51.24M)(35.5M)(18.71M)
Capital Expenditures(506K)(1.62M)(1.23M)(268K)(88K)
Acquisitions (Net)0(851K)000
Purchases of Investments0(73.82M)(73.26M)(58.72M)(33.97M)
Sales of Investments03M104.35M77.55M26.75M
Other Investing Activities0851K01.25M278K
Investing Cash Flow(506K)(72.44M)29.86M19.81M(7.03M)
Debt Repayment(2.85M)29.57M0(5M)(20.72M)
Common Stock Issued73.65M317K395K18.63M61.08M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities26K(886K)(162K)(47K)(59K)
Financing Cash Flow77.15M29.01M233K13.59M40.3M
Effect of Forex Changes00000
Net Change in Cash44.4M(89.95M)(21.14M)(2.1M)14.56M
Free Cash Flow(32.75M)(48.13M)(52.47M)(35.76M)(18.8M)

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.